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Objectives: Drugs that target host cell processes can be employed to complement drugs that specifically
target viruses, and iminosugar compounds that inhibit host a-glucosidases have been reported to show antiviral
activity against multiple viruses. Here the effect and mechanism of two iminosugar a-glucosidase inhibitors,
N-butyl-deoxynojirimycin (NB-DNJ) and N-nonyl-deoxynojirimycin (NN-DNJ), on human influenza A viruses was
examined.
Methods: The viruses examined were a recently circulating seasonal influenza A(H3N2) virus strain A/Brisbane/
10/2007, an older H3N2 strain A/Udorn/307/72, and A/Lviv/N6/2009, a strain representative of the currently
circulating pandemic influenza A(H1N1)pdm09 virus.
Results: The inhibitors had the strongest effect on Brisbane/10 and NN-DNJ was more potent than NB-DNJ. Both
compounds showed antiviral activity in cell culture against three human influenza A viruses in a strain-specific
manner. Consistent with its action as an a-glucosidase inhibitor, NN-DNJ treatment resulted in an altered glycan
processing of influenza haemagglutinin (HA) and neuraminidase (NA), confirmed by MS. NN-DNJ treatment was
found to reduce the cell surface expression of the H3 subtype HA. The level of sialidase activity of NAwas reduced
in infected cells, but the addition of exogenous sialidase to the cells did not complement the NN-DNJ-mediated
inhibition of virus replication. Using reassortant viruses, the drug susceptibility profilewas determined to correlate
with the origin of the HA.
Conclusions: NN-DNJ inhibits influenza Avirus replication in a strain-specificmanner that is dependent on the HA.
Keywords: N-butyl-deoxynojirimycin, NB-DNJ, N-nonyl-deoxynojirimycin, NN-DNJ, N-nonyl-deoxygalactojirimycin, NN-DGJ
Introduction
Influenza A viruses and influenza B viruses cause seasonal human
influenza but influenza A viruses pose an additional risk of zoonotic
infection, with the potential of a host switch and the generation of
pandemic influenza. Influenza epidemics occur almost every year
as the virus undergoes antigenic drift but pandemics are rare and
have occurred with the H1N1 (1918, 1977 and 2009), H2N2 (1957)
and H3N2 (1968) subtype viruses. The 1918 ‘Spanish flu’ pandemic
was by the far the most severe resulting in an estimated 40–100
million deaths worldwide,1 while the 2009 swine flu pandemic
caused an estimated 200000 deaths worldwide.2
Influenza viruses encode two glycoproteins, haemagglutinin
(HA) and neuraminidase (NA), and a transmembrane ion channel
M2. Both glycoproteins play important roles in the virus life
cycle. HA mediates viral attachment via sialic acid receptors
on the surface of a cell and the subsequent fusion of the viral
and endosomal membranes (reviewed in Skehel and Wiley3).
NA, a sialidase, releases progeny virus particles from infected
cells by removing sialic acids from the host cell and the virus
itself.4–6
The current measures against human influenza involve vaccin-
ation and the use of antiviral drugs. The effectiveness of vaccin-
ation is limited by the continuous antigenic drift of the virus as
it evolves, and at the onset of a pandemic there is unlikely to be
an effective vaccine available. Therefore, antiviral drugs can play
an important role in mitigating the effects of influenza. There are
two widely licensed drug classes, the M2 inhibitors (adaman-
tanes) and NA inhibitors (oseltamivir and zanamivir). The M2 inhi-
bitors are currently not recommended for the treatment of
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influenza due to widespread resistance of the circulating human
strains of virus.7,8 There are many examples of the emergence of
virus strains resistant to NA inhibitors in several subtypes, includ-
ing examples of resistance of H1N1pdm09 viruses, H5N1 viruses
and the newly emerged H7N9 viruses. Importantly, resistance
to oseltamivir became widespread in previously circulating
human H1N1 viruses from 2007 until the extinction of these
strains in 2009 and the emergence of the H1N1pdm09 virus.9,10
Drugs that act as antivirals by targeting host cell processes may
lower the risk of drug resistance in a virus and make an attractive
strategy for antiviral therapy, particularly in combination therapy
with drugs specifically targeting viral proteins.
The need to develop novel anti-influenza therapies led us to test
the antiviral activity of two iminosugar compounds, N-butyl-
deoxynojirimycin (NB-DNJ) and N-nonyl-deoxynojirimycin (NN-DNJ),
against human influenza A viruses. These glucose analogue com-
pounds can act as inhibitors of a-glucosidases in the endoplasmic
reticulum (ER) (reviewed in Dwek et al.11); in addition, DNJ derivatives
with a minimum alkyl chain length of at least three carbons can
inhibit ceramide-specific glucosyltransferases (CerGlcT), thus inhibit-
ing glucosphingolipid (GSL) synthesis.11
The antiviral potential of iminosugars has been explored for
human HIV,12,13 hepatitis B,14,15 hepatitis C (HCV),16,17 bovine
viral diarrhoea virus (BVDV)18,19 and the flaviviruses dengue
virus and West Nile virus.20,21 Moreover, long alkyl DNJ derivatives
such as NN-DNJ also exhibit antiviral effects associated with the
alkyl side chain, such as inhibition of the p7 ion channel of HCV in a
genotype-dependent manner.22,23
Many glycoproteins require N-linked glycosylation for folding
and maturation. Nascent N-linked glycoproteins entering the ER
are glycosylated with a high-mannose oligosaccharide precursor
rich in terminal glucose residues that are sequentially removed by
a-glucosidases. Subsequent a-mannosidase activity and further
processing can occur (reviewed in Dwek et al.11). The inhibition
of a-glucosidases by NB-DNJ and NN-DNJ hinders the formation
of monoglucosylated glycans, thus preventing interaction with
the glycan-binding proteins calnexin and calreticulin (whichmedi-
ate protein folding), and so preventing correct protein folding and
glycan modification.
The ER chaperones calnexin and calreticulin mediate the proper
cotranslational folding of both influenza HA and NA24–30 so this
interaction is potentially susceptible to inhibition. Treatment with
glucosidase inhibitors inhibits the interaction of X-31 H3 subtype
HA with calnexin and calreticulin24,25,27,28 and similarly the
interaction of N9 NA with calnexin and calreticulin is also inhib-
ited.29 However, considerable variation in the antiviral effects of
a-glucosidase inhibitors against influenza A viruses has been
observed in different studies. The release of infectious particles of
the influenza A laboratory-adapted H1N1 strains A/Puerto Rico/8/
34 (PR8) andA/NWS/33 (NWS) inMDCK cells treatedwith castanos-
permine (CST),31,32 PR8 in chick embryo cells treated with bromo-
conduritol (BC)33 and the avian influenza virus Rostock (H7N1) in
chick embryo cells treated with N-methyl-deoxynojirimycin
(NM-DNJ)34 was not significantly reduced when compared with
untreated cells. However, a reduction in the release of Rostock
from chick embryo cells on BC treatment,33 and of a reassortant
NWS-N8 virus [which had the HA (H1) of NWS and the NA (N8) of
A/duck/Ukraine/1/63] from MDCK cells on CST treatment was
observed.35 These studies suggest strain-dependent antiviral
effects of a-glucosidase inhibitors on influenza viruses.
Since previous studies have determined antiviral activity against
well-established laboratory strains of influenza Aviruses, we tested
more recent viruses for the antiviral effects of iminosugars. NB-DNJ
has been used in the clinic for over 10 years for the treatment of
Gaucher’s disease without any serious adverse effects, and
NN-DNJ, which has a longer alkyl chain than the latter, is potentially
a more potent antiviral derivative. Here, we show that NB-DNJ and
NN-DNJ exhibit antiviral effects against two viruses of the influenza
A(H3N2) subtype, A/Udorn/307/72 (Udorn) and A/Brisbane/10/
2007 (Brisbane/10), and a virus that is a representative of the
A(H1N1)pdm09 virus, A/Lviv/N6/2009 (Lviv). Our studies show
that NB-DNJ and NN-DNJ inhibit virus replication in a strain-specific
manner, which is likely to be dependent on the origin of the HA. The
inhibition of a-glucosidases in cells alters the glycosylation pattern
of the virus glycoproteins synthesized in the cells, reducing the sur-
face transport of HA and the sialidase activity of NA.
Materials and methods
Cells, viruses and inhibitors
Canine kidneyMDCK II cells came fromPhillips-UniversityMarburg, Germany
and were cultured in MEM (Sigma) containing 10% (v/v) FBS (Perbio),
100 U/mL penicillin/streptomycin (Sigma) and 100 U/mL GlutaMAX
(Invitrogen). Infection was carried out in serum-free MEM containing
100 U/mL penicillin/streptomycin (Sigma), 100 U/mL GlutaMAX (Invitrogen)
and 0.14% (w/v) BSA (Sigma). Influenza A viruses Brisbane/10 (H3N2),
Udorn (H3N2) and Lviv (H1N1) were egg-passaged isolates obtained from
stocks held by the WHO Collaborating Centre for Reference and Research
on Influenza (WHO CC) at the National Institute for Medical Research
(NIMR), Mill Hill, UK. High-growth reassortant viruses X-171b (H3N2) and
X-181 (H1N1) were kindly provided by the National Institute for Biological
Standards andControl (NIBSC), Hertfordshire, UK. The iminosugarcompounds
NB-DNJ, NN-DNJ and N-nonyl-deoxygalactojirimycin (NN-DGJ) were kindly
provided by Oxford GlycoSciences, UK and stocks were made with DMSO as
a solvent. Zanamivir was obtained from GlaxoSmithKline. CPNA, a neuramin-
idase from Clostridium perfringens, was obtained from Roche.
Antibodies and sera
The primary antibodies used were as follows: SH487 sheep serum anti-HA of
Brisbane/10 and SH510 sheep serum anti-HA of A/California/07/2009 (both
used at 1:1000 for western blot and 1:100 for immunofluorescence) were a
kind gift fromMr Robert Newman (NIBSC); PE78 mouse monoclonal anti-NA
of A/California/04/2009 antibody (used at 1:100 for immunofluorescence)
was a kind gift from Dr Richard Webby (St Jude Children’s Research
Hospital, Memphis, USA); R10/8 rabbit serum anti-X-31 (used at 1:100 for
immunofluorescence) was obtained from theWHO CC NIMR; mouse mono-
clonal anti-nucleoprotein (NP) antibody (ab20343, AbCam) was diluted at
1:1000 for immunostaining virus plaques. Secondary antibodies used were
as follows: goat anti-rabbit Alexa Fluor 488, donkey anti-sheep Alexa Fluor
488 and goat anti-mouse Alexa Fluor 594 (all from Invitrogen) were used
at a dilution of 1:1000. Goat anti-mouse horse radish peroxidase conjugate
antibody (Bio-Rad, 172-1011) was used at a dilution of 1:1000 for immuno-
stainingplaques. Rabbit anti-sheepDylight800 antibodywas usedat 1:5000
for western blotting. Ferret sera for HA inhibition (HI) assays, ferret anti-
Brisbane/10 and ferret anti-Lviv, both receptor-destroying-enzyme treated,
were obtained from the WHO CC NIMR.
Primers
All primers used in this studywere obtained from theWHOCCNIMR. Primer
sequences are available as Supplementary data at JAC Online.
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Generation and characterization of reassortant viruses
Confluent monolayers of MDCK cells were infected at anmoi of 10 pfu/cell
with different ratios of the two viruses Brisbane/10 and Lviv, essentially as
described by Baigent et al.36 The subtype of HA was determined by HI
assays with ferret serum raised against Brisbane/10 or Lviv. The subtype
of NAwas determined following isolation of RNA from the virus in allantoic
fluid and amplification of the genomic segment in a one-step RT–PCRwith
N1- and N2-specific primers. All genomic segments of the reassortant
H3N1 virus were identified by nucleotide sequence analysis.
RNA extraction, RT–PCR and sequence analysis
All viral RNA extractions were performed using the QIAamp Viral RNA Mini
Kit (Qiagen) using on-column DNase digestion (Qiagen). Reverse transcrip-
tion was performed with the Uni12 primer using the Verso cDNA kit
(Thermo Scientific). PCR reactions were performed using Pfu Ultra II fusion
HS polymerase (Stratagene #600674-51) according to themanufacturer’s
protocol. PCR products were purified for sequencing by Illustra GFX PCR
DNA and Gel Band Purification kit (GE Healthcare). Sequencing reactions
were performed using BigDyew Terminator v1.2 Cycle Sequencing Kit
(Applied Biosystems) (according to the manufacturer’s instructions) and
samples were run on an ABI 3730xI DNA Analyser.
Cell viability assay
Confluent monolayers of MDCK cells were treated with increasing concen-
trations ofNB-DNJ orNN-DNJ and equivalent amounts of DMSO, serving as
a control, in serum-free medium for 48 h. Cells were subsequently treated
with CellTiter-BlueTM (Promega) reagent according to the manufacturer’s
protocol and fluorescencewasmeasured (560Ex/590Em). As a positive con-
trol for cytotoxicity, cells were treated with digitonin (0.5 mg/mL; Sigma)
for 10 min before the addition of CellTiter-BlueTM reagent. The CC50 and
CC90 were calculated for each experiment by linear interpolation.
Virus titration
Plaque assay
Confluent monolayers of MDCK cells were infected with 10-fold serial dilu-
tions of virus and plaque assays were performed using Avicel overlay
medium, essentially as described by Matrosovich et al.37 Cells were fixed
and stained at various times post-infection (pi) with 4% (v/v) formalde-
hyde and 0.2% (w/v) toluidine blue in PBS, or the plaques were immunos-
tained for influenza NP as described by Sullivan et al.38 Plaque numbers
were scored and plaque size was measured to the nearest 0.1 mm using
a PEAKTM Scale Lupe (×10 magnification).
HA assay
HA assays were performed using 0.75% (v/v) turkey red blood cells/PBS as
described in the WHO methods.39
Virus yield assays and plaque reduction assays
Single-cycle high-moi virus yield assay
Confluent monolayers of MDCK cells were washed twice with PBS and
infected at an moi of 10 pfu per cell for 1 h at room temperature. After
removal of the inoculum, cells were washed four times with PBS, treated
with the indicated concentrations of NB-DNJ and NN-DNJ in serum-free
virus growthmedium and incubated at 378C, 5% CO2. A DMSO control cor-
responded to an amount of DMSO in the medium equivalent to that pre-
sent at the highest concentration of the drug. At 3 h pi, the medium was
removed, the cells were washed four times with PBS and themediumwith
the same concentrations of drug was replaced. The cells were then again
incubated at 378C, 5% CO2. At 20 h pi the virus yield from cell culture
supernatants was measured by HA assays and by plaque assays per-
formed in duplicate. Mean HA titres or infectious virus titres were calcu-
lated as a percentage of HA or infectious virus titres, respectively, from
untreated cells for each drug treatment condition in an experiment. The
IC50 and IC90 of viral growth were calculated for each experiment by linear
interpolation. To determinewhether the presence ofNN-DNJ in the cell cul-
ture supernatants affected the infectious virus titres measured by plaque
assay or HA titres in the HA assay, different concentrations of NN-DNJ
were added to a fixed volume of each virus used in these studies. For
plaque assays, MDCK cells were infected at an moi of 0.0001 pfu/cell
with inoculum containing NN-DNJ or untreated inoculum and, after
removal of the inoculum, overlaid with medium in the absence of drug.
Plaques were assessed as described earlier. Similarly, HA assays were per-
formed on viruses in the presence of the highest concentration of NN-DNJ
present in the cell culture supernatants or a control lacking drug. The pres-
ence of NN-DNJ did not affect the measurements in either assay.
Multicycle plaque reduction assay
Confluent monolayers of MDCK cells were washed twice with PBS and
infected at an moi of 0.0001 pfu per cell for 1 h at room temperature.
After removal of the inoculum, the cells were treated with increasing con-
centrations of drug in the overlay containing trypsin. The DMSO control
represents an amount of DMSO in the overlay equivalent to that present
in the overlay with the highest concentration of drug used. At time
≥30 h pi, dependent on the strain, the overlay was removed, and the
cells were fixed with formaldehyde and then stained with toluidine blue
or immunostained for influenza NP. Plaque assays were performed in
duplicate in each experiment. The mean plaque number as a percentage
of the mean plaque number from the untreated cells was calculated for
each drug condition in an experiment. To assess the effects of the treat-
ments on plaque size, 30 plaques were measured (to the nearest
0.1 mm) per drug treatment condition using a PEAK Scale Lupe×10. The
median plaque size as a percentage of the median plaque size from the
untreated cell control was calculated for each drug condition in an experi-
ment. IC50 and IC90 values were calculated for each experiment by linear
interpolation.
Quantification of cells immunostained for influenza NP
Confluent monolayers of MDCK cells in 96-well plates were washed twice
with PBS and then infected at an moi of 0.1 pfu per cell for 1 h at room
temperature. After removal of the inoculum, the cells were washed
twice with PBS and treated with 62.5 mM NN-DNJ or the equivalent
DMSO control in serum-free medium. At 6 h pi the cells were fixed and
immunostained for NP as described above. The 96-well plates were
scanned with a house-assembled scanner using an IX70 Olympus micro-
scopewith a×10 objective (numerical aperture¼0.3), using Surveyor soft-
ware (Objective Imaging Ltdw). The images were quantified using the
high-throughput quantification method described by Sullivan et al.38
NP-positive cells were counted based on their size in pixels, whichwas cali-
brated visually in advance. NP-positive cells from triplicatewells were aver-
aged for each drug treatment in an experiment. Finally, the mean number
of NP-positive cells from drug-treated cells as a percentage of mean
NP-positive cells from untreated cells was calculated for each experiment.
Purification of virus from cell culture supernatants
Confluent monolayers of MDCK cells were washed twice with PBS, infected
at an moi of 10 pfu per cell for 1 h at room temperature and treated as in
the virus yield assay. At 19 h pi for Brisbane/10 and Lviv, and 11 h pi for
Hussain et al.
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Udorn, the cell culture supernatants were harvested and clarified of cells
by centrifugation, and virus was purified by ultracentrifugation at
157000 g for 3 h at 48C through a 30% (w/v) sucrose/PBS cushion. Virus
proteins were separated by SDS-PAGE on 10% polyacrylamide gels under
reducing conditions and protein bands were visualized by Coomassie blue
staining. Gels were imaged using the scanner Epson perfection v750 pro
and densitometry was performed using ImageJ software.
qRT–PCR to detect virus purified from tissue culture
supernatants
Cell culture supernatants from high-moi infections were harvested at 9 h pi
and clarified, and virus was purified by ultracentrifugation as described
above. Virus pellets were resuspended in PBS and RNA was extracted as
described earlier. Reverse transcription was performed with Uni12 primer
using the Omniscript RT kit (Qiagen). The qRT–PCR reactions were
performed using TaqManw Fast Universal PCR Master Mix (Applied
Biosystems) with primers and probes from the CDC to detect influenza
virus Segment 7. Samples were run on Applied Biosystems 7500 Fast
Real-Time PCR machine. qRT–PCR was performed in triplicate per sample
and mock-infected-cell, no-RT and no-template controls were used in each
experiment. CT values from virus pellets fromNN-DNJ-treated cells were sub-
tracted from control cells infected with that virus (DCT) and Segment 7
expression from virus purified from NN-DNJ-treated cells was calculated as
22(DCT) and expressed as a percentage of the control (DMSO-treated cells).
35S-labelling of viral proteins
Cells were infected at an moi of 10 pfu per cell and at 6 h pi cells were
labelled with 100 mCi/mL [35S]methionine/cysteine (EXPRESS 35S Protein
Labelling Mix, Perkin-Elmer # NEG072002MC) in Met-Cys free medium in
the presence of drug or DMSO for 40 min and analysed essentially as
described by McCauley and Penn.40
Immunofluorescence and quantification of protein
expression
Cells were infected at an moi of 5 pfu per cell and at 8 h pi cells were fixed
in 4% (w/v) paraformaldehyde in PBS for 20 min at room temperature and
then washed three times with PBS. Cells were immunostained with virus
strain-specific primary Ab raised against HA or NA diluted in 0.35% BSA
(w/v) in PBS for 1 h at room temperature and were washed three times
with PBS and stained with Alexa Fluor 488- or 594-conjugated secondary
Ab diluted in 0.35% BSA (w/v) in PBS for 1 h at 48C; they were then washed
three times with PBS. Cells were stained with 0.35 mg/mL DAPI and
mounted onto slides in Prolongw Gold antifade reagent (Invitrogen).
Images were acquired on a DeltaVision RT microscope (Applied
Precision Ltd, USA) using a ×100 objective (numerical aperture¼1.4)
onto a CoolSNAP HQ CCD camera (Photometrics Ltd) obtaining
Z-sections of 0.2 mm to a depth of 7 mm with appropriate filters and
deconvolved using the softWoRx software (AppliedPrecisionw). Then
16-bit 2D maximal intensity projections were generated using Fiji soft-
ware. The overall fluorescence intensity above the background for each
infected cell was determined and the area of the cell was measured.
The overall fluorescence intensity for each cell is plotted as number of
fluorescent pixels per mm2.
Sialidase activity of NA from post-nuclear supernatants
Confluent monolayers of MDCK cells, infected at an moi of 5 pfu per cell,
were subsequently harvested on ice, washed in 1 mM EDTA in PBS and
removed with a cell scraper, followed by centrifugation for 10 min at
1200 g at 48C. The pellets were resuspended in isotonic buffer (20 mM
Tris-HCl pH 7.4, 140 mM NaCl), at the same volume as the pellet, and a
20-fold volume of hypotonic buffer [20 mM Tris-HCl pH 7.4, with PI
(Sigma P8340) diluted 1:100] was added. Cells were sheared by passing
them 15 times through a 21 gauge needle and five times through a
27 gauge needle and nuclei were pelleted by centrifugation at 150 g for
5 min at 48C. Protein concentrations from post-nuclear supernatants
were normalized by quantification with a Bradford assay (Bio-Rad) prior to
a sialidase assay using 2′-(4-methylumbelliferyl)-a-D-N-acetylneuraminic
acid (MuNANA).39
MS analysis of glycans of glycoproteins from purified virus
Virus from cell culture supernatants was purified by ultracentrifugation as
described earlier and the virus proteins were separated by SDS-PAGE under
reducing conditions. The influenza glycoprotein bands were confirmed by
MS. In brief, this involved the excision of Coomassie blue-stained bands cor-
responding to themolecularweights of HAandNA, and the reduction, alkyl-
ation and removal of N-linked glycans by in-gel digestion with
peptide-N-glycosidase F (PNGase F; Roche Life Sciences). Peptide fragments
were generated by in-gel digestionwith chymotrypsin, trypsin and elastase.
Digested protein acidified to a final concentration of 0.1% trifluoroacetic
acid was loaded onto an ultimate 3000 nanoRSLC (rapid separation LC)
HPLC using a stepwise gradient of acetonitrile and 0.1% formic acid.
Eluant was introduced into a Linear Trap Quadrupole Orbitrap Velos Pro
(Thermo Scientific) using a Proxeon nano-electrospray source (Thermo
Scientific). Subsequent to tandem MS, proteins were identified using the
search engine Mascot 2.4 (Matrix Science, UK) and the data were searched
against a custom database consisting of the sequences obtained by the
sequencing of HA and NA from the RT–PCR products of viral RNA.
For theMS analysis of the glycans in the glycoproteins, Coomassie blue-
stained SDS-PAGE gel bands of influenza glycoproteins HA and NA were
excised, washed five times alternately with acetonitrile and deionized
water and rehydrated with a 3000 U/mL of aqueous PNGase F (New
England Biolabs, Ipswich, USA) solution in gel, as described by Ku¨ster
et al.41 The gel bands were subsequently incubated at 378C for 12 h and
the enzymatically released glycans were eluted with water. Samples were
diluted into 3 mL of H2O. Samples of 1 mL volume were cleaned with a
Nafion 117 membrane, diluted with 5 mL of H2O and 5 mL of methanol
plus 1 mLof 1 MH3PO4 solution (to ensure the complete formation of phos-
phate adducts in the electrospray spectra) and centrifuged for 1 min at
10000 g. They were examined by ion-mobility, negative-ion MS/MS elec-
trospray ionization on a Waters Synapt G2 mass spectrometer (Waters
MS Technologies, Manchester, UK) with sample introduction with Waters
thin-wall nanoflow capillaries.
The electrospray ionization capillary voltage was 1.2 kV, the cone volt-
age was 20–180 V and the source temperature was maintained at 808C.
The T-wave velocity and peak height voltages were 450 m/sec and 40 V,
respectively. The T-wave mobility cell contained nitrogen and was oper-
ated at a pressure of 0.55 mbar. Fragmentation was performed after
mobility separation in the transfer cell with argon as the collision gas.
The instrument was externally calibrated with sialylated N-glycans
released from bovine fetuin. Data acquisition and processing were carried
out using the Waters Driftscope (version 2.1) software and MassLynxTM
(version 4.0). The scheme devised by Domon and Costello42 was used to
name the fragment ions and data interpretation followed that described
by Harvey et al.43–46 The diagnostic ions discussed below have all been
confirmed by the spectra of known reference compounds. For quantitative
measurements, the peak heights of the monoisotopic and isotope ions
were summed. The value for each glycan is expressed as a percentage
of the total glycans. These data are for relative comparisons only because
of the possible differing ion yields from glycans of different types.
Graphs and statistical analysis
Graphswere generated using GraphPad Prism version 5.04. CC50, CC90, IC50
and IC90 valueswere determined using linear interpolation from graphs on
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which the percentage inhibition was plotted against increasing drug con-
centrations. Two-tailed, unpaired t-tests were performed using GraphPad
Prism version 5.04. The Mann–Whitney rank sum test (Sigma Plot version
12.0) was used to statistically analyse the differences in plaque size mea-
surements. A P value,0.05 indicated that the difference between the two
datasets was statistically significant.
Results
Iminosugars inhibit influenza A virus infection in
single-cycle and multicycle assays
Cytotoxicity of NB-DNJ and NN-DNJ on MDCK cells
To determine the concentrations of NB-DNJ and NN-DNJ that can
be used to test antiviral activity without affecting cell viability, the
CellTiter-BlueTM cell viability assaywas used. MDCK cells were trea-
ted with increasing concentrations of NB-DNJ or NN-DNJ or the
equivalent amounts of DMSO in serum-free medium for 48 h
before the addition of CellTiter-BlueTM reagent, and fluorescence
was recorded. Cell viability was not affected at concentrations
up to 500 mM NB-DNJ and 200 mM NN-DNJ. The CC50 and CC90
values of NB-DNJ on MDCK cells could not be specifically deter-
mined due to the toxicity of the DMSO diluent so have been
described as .1 mM, at which the same concentration of DMSO
alone resulted in undetectable cytotoxicity. NN-DNJ was more
cytotoxic; the CC50 and CC90 values were 559+112 mM and
859+243 mM (mean+SD from three independent experiments),
respectively.
Effects of NB-DNJ, NN-DNJ and NN-DGJ on a single cycle
of virus replication
The antiviral effects of NB-DNJ and NN-DNJ on the yield of viruses
from cells infected with Udorn, Brisbane/10 and Lviv, at high moi
(¼10 pfu/cell) and treated with drug after the infection period,
were examined. HA titres and infectious virus titres of cell culture
supernatants harvested at 20 h pi are shown in Figure 1. The
DMSO controls for all three viruses show that DMSO does not
affect virus replication in these assays, as shown by both the HA
titres and infectious virus titres obtained from DMSO-treated cells
compared with untreated cells.
For all three viruses tested, the reduction of virus yield mea-
sured by both HA titre and infectivity with increasing concentra-
tions of NB-DNJ were similar (Figure 1a i and ii) and IC50 and
IC90 values were calculated for each virus and each drug. The
IC50 values (Table 1) for HA titre and the release of infectious
virus from NB-DNJ-treated cells infected with the two H3N2
viruses and the pandemic H1N1 virus were in a similar range,
between 20–50 mM. At the highest concentration of NB-DNJ
used in this study, 312.5 mM, infectious virus titres from three
independent experiments were reduced to 8%–10% of the
untreated control for Udorn, 1%–2% of the control for Brisbane/
10 and 23%–25% of the control for Lviv.
For each virus tested, as seen with NB-DNJ, the reduction in HA
titre of virus from the supernatants of drug-treated cells corre-
sponded to the reduction in infectious virus titre from these super-
natants with increasing concentrations of NN-DNJ. All three
viruses had low micromolar IC50 values (Table 1). A variation
between virus strains was observed in the IC90 values. Brisbane/
10 had the lowest IC90 values when assessed as HA titres and
infectious virus titres. IC90 values could not be determined for
Lviv. At the highest concentration of NN-DNJ used, 62.5 mM, the
infectious virus titre from three independent experiments was
reduced to between 5%–7% of the untreated control for
Udorn, 0.1%–0.4% of the control for Brisbane/10 and 11%–
14% of the control for Lviv (Figure 1b i and ii). Therefore,
Brisbane/10 was the virus that was most susceptible to NB-DNJ
and NN-DNJ. It must be noted that the presence of NN-DNJ in
the cell culture supernatants did not affect the virus titre mea-
sured by plaque or HA assay as described in the Materials and
methods section (data not shown).
The antiviral effects of NN-DGJ, which is not an a-glucosidase
inhibitor but inhibits GSL synthesis, were also determined. IC50
values were not obtained at 62.5 mM NN-DGJ for the three viruses
and no inhibition of virus yield in the single cycle of replication
assays was seen. At 62.5 mM NN-DGJ for Udorn, Brisbane/10 and
Lviv, respectively, the HA titres were 117%+19%, 75%+15%,
60%+10% of the values for untreated cells and the infectious
titres were 97+20%, 71+21% and 85%+16% of the values
seen in untreated cells.
Effects of NN-DNJ and NN-DGJ over multiple cycles
of replication
The action of NN-DNJ on human influenza A virus replication was
also examined over multiple cycles of replication using plaque
reduction assays. Equivalent concentrations of DMSO did not affect
plaque formation in these experiments. For Udorn and Lviv, a
,40% reduction in plaque number was observed at the highest
concentrations of NN-DNJ (Figure 1b iii); hence an IC50 was not
obtained for plaque number for cells infected with these two
viruses. However, in Brisbane/10-infected cells a profound effect
of the drug on plaque number was observed. At concentrations
of 12.5 mMNN-DNJ andhigher, an incomplete formation of plaques
was observed in the cell monolayers. Toluidine blue staining
showed circular areas of lighter stained cells. IC50 and IC90 values
for plaque number were 8.2+2.4 mM and 22.0+9.5 mM, respect-
ively (Table 1). Therefore,NN-DNJ inhibited influenza Avirus replica-
tion in a strain-specific manner over multiple cycles of infection.
The effect of NN-DNJ on the size of the virus plaques was also
assessed. For all three viruses, plaque size was reduced with
increasing concentrations of NN-DNJ. Brisbane/10 was the most
susceptible to inhibition by NN-DNJ (Figure 1b iv) and it was pos-
sible to determine IC50 and IC90 values (Table 1). The IC50 values
for the median plaque size of all viruses are shown in Table 1, and
an IC90 value could be determined for the effect of NN-DNJ on the
release of Brisbane/10 from infected cells. The non-parametric
Mann–Whitney rank sum test was used to assess the statistical
significance of the reduction in plaque size for NN-DNJ-treated
cells compared with untreated cells. For Udorn-infected cells trea-
ted with a concentration of ≥ 0.1 mM NN-DNJ, and for Brisbane/
10- and Lviv-infected cells treated with a concentration of
≥0.5 mM NN-DNJ, the rank sum analysis showed that the differ-
ence in plaque size was statistically significant compared with
the untreated control (P values in Table S1).
In plaque reduction assays with NN-DGJ, neither plaque
number nor plaque sizewas reduced by 50%at anyof the concen-
trations tested; hence IC50 values were not obtained for plaque
number or plaque size. For Udorn, Brisbane/10 and Lviv, respect-
ively, at 62.5 mM NN-DGJ, plaque number was reduced to
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Figure 1. Iminosugar inhibition of single andmulticycle replication of different human influenza A viruses. (i) HA titres and (ii) infectious virus titres from
single-cycle high-moi assays performed on MDCK cells infected with Udorn, Brisbane/10 and Lviv and treated with (a) NB-DNJ and (b) NN-DNJ. Mean
percentage HA titre or infectious virus titres were calculated as a percentage of HA titre or infectious virus titres, respectively, from untreated cells for
each drug treatment condition in an experiment. (b) (iii) Plaque number and (iv) plaque size from plaque reduction assays performed on MDCK cells
infected with the three viruses and treated with NN-DNJ. Plaques were fixed and stained with toluidine blue. The DMSO control is a DMSO
concentration equivalent to the highest concentration of drug tested. In the graphs, the means and standard deviations of three independent
experiments are plotted against increasing drug concentration.
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74+16%, 60+10% and 73+8% of untreated cells, respectively,
and plaque size was reduced to 88+20% and 76+4% for Udorn
and Brisbane/10, with no effect on Lviv (104+9% of untreated
cells) over three independent experiments.
NN-DNJ does not affect virus entry on treatment of cells
during infection
In multicycle replication assays, NN-DNJ is present on cells
throughout the period of infection. NN-DNJ inhibits the p7 ion
channel of HCV22,23 in a genotype-dependent manner,23 which
does not depend on its glucosidase inhibition but rather is due
to the alkyl side chain. Although the HCV p7 and influenza M2
ion channels differ in their structure and function, certain inhibi-
tors such as amantadine have efficacy against both,47,48 albeit
at different concentrations. Therefore, to examine a potential
effect of NN-DNJ on the early events of influenza virus replication
involving the influenza M2 ion channel, cells were infected with
the amantadine-susceptible strain Udorn in the presence of
amantadine, as a control, orNN-DNJ (Figure S1a), or were infected
with the three different influenza strains in the presence of
NN-DNJ (Figure S1b) with drug also present after infection.
Infected cells were quantified by counting the number of influ-
enza NP-positive cells at 6 h pi. Amantadine treatment resulted
in a significant reduction in the number of NP-positive cells to
14% of the untreated control. However, in these experiments,
NN-DNJ had at most only a minor impact on the ability of virus
to initiate infection.
NN-DNJ reduces release of virus particles from cells
NN-DNJ reduced the release of infectious virus from the cells and
the HA titres corresponded to this reduction in infectivity
(Figure 1b). In order to determine whether NN-DNJ affects the
total release of virus-like particles that might not be either infec-
tious or able to bind to red blood cells, single-cycle high-moi virus
yield assays were performed, treating the cells after infection with
62.5 mM NN-DNJ or the equivalent DMSO control in the super-
natant, and the production of virus particles was assessed. Virus
particles from clarified supernatants were pelleted by ultracentri-
fugation through a 30% sucrose cushion. Equal volumes from
each sample were taken and proteins from purified virus were
separated by SDS-PAGE under reducing conditions (Figure 2). It
is not possible to estimate the levels of virus protein between
treatments due to possible handling losses during virus purifica-
tion. However, the ratio of stained uncleaved HA, HA0, to NP can
be estimatedwithin a sample. This was done for two independent
experiments. For Lviv there was no discernible difference between
NN-DNJ- and control DMSO-treated cells, but for both Udorn and
Brisbane/10 therewas a recognizable drop in the HA content of the
virion, manifested by a reduction in the ratio of Coomassie-blue-
stained HA to NP by between one-third and two-thirds for both
Udorn and Brisbane/10.
To quantify further the reduction in the number of virus parti-
cles purified from NN-DNJ-treated cells, qRT–PCR was performed
on RNA extracted from virus pellets that had been obtained from
the same amount of cell culture supernatant for each sample. The
levels of influenza Segment 7 (encoding M) from purified virus
from NN-DNJ-treated cells over three independent experiments
were 4%–13%, 0.5%–3%, and 15%–40%, for Udorn, Brisbane/
10 and Lviv in drug-treated cells, respectively, compared with
the control DMSO-treated cells. Fewer virus particles are released
from drug-treated cells and it appears that NN-DNJ treatment
reduces the titre of infectious virus released (Figure 1 and
Table 1) by reducing the total number of virions released (shown
by SDS-PAGE and qRT–PCR). For Udorn, Brisbane/10 and Lviv,
respectively, HA titres from NN-DNJ-treated cells were 6%–8%,
0% and 13%–25% of the control and infectious titres were
6%–8%, 0.2%–0.8% and 12%–20% of the control. With the
overlap of these values for each virus as assessed by SDS-PAGE
or RT–PCR, there is no evidence to suggest the presence of a size-
able proportion of virus that is released from the cell but is unable
to initiate further replication.
Table 1. Antiviral effects of NB-DNJ, NN-DNJ and NN-DGJ over single and multiple cycles of replication
Subtype Virus
Single-cycle replication assay Multicycle replication assay
HA titre infectious virus titre plaque number plaque size
IC50 (mM) IC90 (mM) IC50 (mM) IC90 (mM) IC50 (mM) IC90 (mM) IC50 (mM) IC90 (mM)
NB-DNJ (mM) H3N2 Udorn 21.7+15.9 280.0+23.6 34.7+11.2 296.1+16.1 ND ND ND ND
H3N2 Brisbane/10 43.8+6.5 207.0+95.3 43.6+11.8 250.0+10.4 ND ND ND ND
H1N1 Lviv 51.3+11.3 .312.5 46.5+12.2 .312.5 ND ND ND ND
NN-DNJ (mM) H3N2 Udorn 0.5+0.0 32.0+14.7 0.4+0.2 16.2+4.7 .62.5 .62.5 6.6+5.5 .62.5
H3N2 Brisbane/10 1.5+1.0 5.8+1.9 1.73+0.3 10.3+0.3 8.2+2.4 22.0+9.5 4.1+1.2 10.9+0.3
H1N1 Lviv 2.5+0.0 .62.5 1.9+0.8 .62.5 .62.5 .62.5 1.8+0.3 .62.5
NN-DGJ (mM) H3N2 Udorn .62.5 .62.5 .62.5 .62.5 .62.5 .62.5 .62.5 .62.5
H3N2 Brisbane/10 .62.5 .62.5 .62.5 .62.5 .62.5 .62.5 .62.5 .62.5
H1N1 Lviv .62.5 .62.5 .62.5 .62.5 .62.5 .62.5 .62.5 .62.5
ND, not determined.
Single-cycle high-moi assays and multicycle plaque reduction assays were performed on MDCK cells infected with Udorn, Brisbane/10 and Lviv. Mean
IC50 and IC90 values were calculated from three independent experiments;+ represents the standard deviation from the mean of three independent
experiments.
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Analysis of virus glycoproteins synthesized in
NN-DNJ-treated cells shows alteration in glycan
processing
To examine the effects of NN-DNJ on the glycoprotein processing
of influenza A virus glycoproteins, MDCK cells infected with Udorn,
Brisbane/10 and Lviv and treated with NN-DNJ or the equivalent
DMSO control were metabolically labelled with [35S]methionine/
cysteine at 6 h pi for 40 min to allow time for synthesis and post-
translationalmodification. Infected cell lysates were separated by
SDS-PAGE under reducing conditions (Figure S2). For all three
viruses, a reduction in electrophoretic mobility of HA0 synthesized
in NN-DNJ-treated cells was seen when compared with DMSO-
treated cells, consistent with a-glucosidase inhibition by NN-DNJ
and a corresponding effect on the mobility of HA0. Importantly,
there was no marked difference in the amounts of either HA0 or
NP synthesized over this 40 min period between drug-treated
samples and the DMSO control.
MS analysis was used to compare the glycan composition of the
influenza glycoproteins from virus purified from NN-DNJ-treated
and control (DMSO-treated) cells (Figure 3 and Table S2). Glycans
from the untreated cells were predominantly high-mannose oligo-
saccharides with differences in the glycan composition of HA
in each of the strains: Brisbane HA had a higher proportion of
Man9GlcNAc2 (M9N2) (10%) in comparison with Lviv and Udorn
(1%–3%) but a lower percentage of M6N2. Iminosugar treatment
increased the proportion of tri-glucosylated glycans (Glc3H7N2,
Glc3H8N2 and Glc3H9N2) from undetectable in the control
DMSO-treated samples to 26.4% (Udorn), 21.8% (Brisbane) and
37.3% (Lviv) of total glycans, respectively, in HA from virus grown
in the presence of NN-DNJ, producing a substantial change in the
glycan profiles consistent with an inhibition of ER a-glucosidases
Influenza H3 HA synthesized in NN-DNJ-treated cells
shows reduced surface expression
Light microscopy was used to visualize the surface expression of
influenza glycoproteins from immunostained NN-DNJ-treated
cells. Figure 4(a) shows the immunostaining of surface HA from
Brisbane/10-infected MDCK cells treated with 62.5 mM NN-DNJ
or the equivalent DMSO control. HA is seen to be present within
foci in the control cells and a visible reduction of HA incorporation
into foci was observed in NN-DNJ-treated cells. Fluorescence on
the cell surface was quantified from images by measuring the
overall fluorescent intensity from the cells (Figure S3a, with an illu-
strated example shown in Figure 4) and then plotting it as the
number of fluorescent pixels per unit area for each cell versus
the cell treatment condition. A two-tailed unpaired t-test showed
that therewas a statistically significant reduction in the number of
fluorescent pixels per unit area for cells treatedwith NN-DNJ com-
pared with the DMSO-treated control cells (P,0.0001). Light
microscopy of immunostained surface HA on Udorn-infected
MDCK cells in Figure 4(b) shows filamentous virions (indicated by
arrow heads). As seen with Brisbane/10, a visible reduction in HA
incorporation into foci was observed for NN-DNJ-treated cells
compared with DMSO-treated cells, and a reduction in viral fila-
ments incorporating HA was observed. A quantification of overall
fluorescence of Udorn HA on the surface of DMSO-treated cells
(Figure S3b) showed that the number of fluorescent pixels per
unit area from different cells was more variable for Udorn than
for Brisbane/10 (Figure S3a) and this difference is likely to be
due to the more varied morphology of the budding virus struc-
tures observed. The Mann–Whitney rank sum test showed a stat-
istically significant reduction in the number of fluorescent pixels
per unit area for cells treated with NN-DNJ compared with the
DMSO-treated control cells (P,0.0001).Therefore, a reduction in
the surface expression of HA on Udorn was observed from
NN-DNJ-treated cells compared with the control.
The surface expression of both HA and NA for Lviv was visua-
lized by immunostaining and light microscopy (Figure 4c).
Co-localization of HA and NA was observed, as shown in the
merged figure. A quantification of the overall fluorescence inten-
sity of HA and NA on the surface of cells in Figure S3(c) (i and ii)
showed no significant difference (by Mann–Whitney rank sum
test) between drug-treated and DMSO-treated cells.
These results demonstrate a reduction in the expression of sur-
face HA on NN-DNJ-treated cells infected with Udorn and
Brisbane/10 when compared with DMSO-treated cells, but
NN-DNJ had no discernible effect on the surface expression of
HA or NA for Lviv.
Influenza NA synthesized in NN-DNJ-treated cells shows
reduced sialidase activity
To investigate the antiviral effects of an NN-DNJ-mediated
alteration of glycan processing on the functionality of NA in
250
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Figure 2. SDS-PAGE gel showing virus purified from cell culture
supernatants of NN-DNJ-treated cells. Single-cycle high-moi assays were
performed on MDCK cells infected at an moi of 10 pfu/cell with Udorn,
Brisbane/10 and Lviv and treated with 62.5 mM NN-DNJ or an equivalent
DMSO control. At 19 h pi for Brisbane/10 and Lviv and 11 h pi for Udorn, cell
culture supernatantswere harvested. Viruswas purified from supernatants by
ultracentrifugation through a 30% sucrose cushion. Proteins from pellets
were separated by SDS-PAGE on a 10% polyacrylamide gel under reducing
conditions and protein bands (HA0, NP and Matrix protein M1) were
visualized by Coomassie blue staining.
Imino sugar inhibition of influenza viruses
143
JAC
 at Edinburgh U
niversity on July 8, 2015
http://jac.oxfordjournals.org/
D
ow
nloaded from
 
NN-DNJ-treated cells, the enzymatic activity of NA synthesized in
NN-DNJ-treated cells was compared with that in DMSO-treated
cells. MDCK cells were infected with Udorn, Brisbane/10 or Lviv at
an moi of 5 pfu per cell and treated with 62.5 mM NN-DNJ or the
equivalent DMSO control. The sialidase activity of NA synthesized
in cells was examined by a MuNANA assay of post-nuclear super-
natants harvested at several time points pi. A reduction in sialidase
activity was seen from NA synthesized in NN-DNJ-treated cells for
all three viruses when compared with the DMSO control. For Udorn,
Brisbane/10 and Lviv, the reduction in sialidase activity of NA from
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Figure 3. MS analysis of the glycan composition of influenza glycoproteins from virus purified from NN-DNJ-treated cells. MDCK cells were infected at an
moi of 10 pfu/cell with Udorn, Brisbane/10 and Lviv and treated with 62.5 mM NN-DNJ (b) or the equivalent DMSO control (a). Virus from cell culture
supernatants was purified by ultracentrifugation, proteins from pellets were separated by SDS-PAGE, glycoprotein bands were cut and digested
glycans were analysed by MS as described in the Materials and methods section. Glycans (M¼mannose, G¼galactose, Glc¼glucose, N¼N-acetyl
glucosamine, F¼ fucose) from Udorn HA, Brisbane/10 HA and Lviv HA and NA are expressed as a percentage of the total glycans.
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NN-DNJ-treated cells was 35%–45%, 30%–40% and 45%–
60%, respectively, compared with the DMSO control over three
independent experiments.
Therefore, although a reduction in the sialidase activity of NA
synthesized from cells treated with the inhibitory concentration
of 62.5 mM NN-DNJ was observed, the reduction did not follow
the strain-specific pattern of an NN-DNJ-mediated inhibition of
virus release.
Antiviral effect of NN-DNJ on virus replication is not
complemented by the addition of an exogenous sialidase
To address whether the reduction in sialidase activity of NA
synthesized in NN-DNJ-treated cells played a role in the reduction
in the release of virus particles from the cell surface, the ability of
exogenous NA added to the medium to complement sialidase
activity was examined.
Figure 5 shows representative plaque reduction assays. In
Udorn-, Brisbane/10- and Lviv-infected cells, the addition of
0.5 mU/mL CPNA, 0.05 mU/mL CPNA and 0.01 mU/mL CPNA,
respectively, restored plaque formation in the presence of zanami-
vir, showing that exogenous NA complemented the zanamivir-
mediated inhibition of sialidase activity. For Udorn, the addition of
CPNA to untreated and DMSO-treated cells resulted in a discernible
increase in plaque size; for the other two viruses, however, there
was no difference in plaque size between the untreated control
cells or DMSO-treated control cells with or without CPNA as
assessed by the Mann–Whitney rank sum test (data not shown).
For all three viruses, the reduction in plaque sizewith inhibitory con-
centrations of NN-DNJ was not enhanced by the addition of CPNA.
Interestingly, for both Udorn and Brisbane/10 but not for Lviv, pla-
que formation at these NN-DNJ concentration(s) was inhibited by
CPNA. For Lviv, the difference in plaque size between cells treated
with 62.5 mM NN-DNJ with or without CPNA was not statistically
significant by Mann–Whitney rank sum test (data not shown).
These results show that the addition of exogenous NA does
not restore plaque size in NN-DNJ-treated cells. Therefore, the
reduction in sialidase activity observed for all three viruses
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Figure 4. Surface expression of HA or NA in cells infected with Udorn, Brisbane/10 or Lviv treatedwith or withoutNN-DNJ. MDCK cells were infected at an
moi of 5 pfu/cell with (a) Brisbane/10, (b) Udorn and (c) Lviv and treated with 62.5 mM NN-DNJ or the equivalent DMSO control. At 8 h pi, the cells were
fixed and immunostained for HA or NA. Images were acquired on a DeltaVision RT microscope using a×100 objective (numerical aperture¼1.4)
obtaining Z-sections of 0.2 mm to a depth of 7 mm. Images were deconvolved and 2D maximal intensity projections were generated using Fiji
software. In the Udorn and Brisbane/10 merge images, HA is shown in green. In the Lviv single panels and Merge images, HA is shown in green and
NA in magenta. Bars, 10 mm. A line (shown in yellow) was drawn across a cell where indicated and plots of pixel intensity versus distance (mm) for
the line are shown next to the relevant image; the quantification of 30 such cells per treatment condition is shown in Figure S3. Arrow heads
indicate filamentous virions.
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Figure 4. Continued
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seems not to be a major contributor to the NN-DNJ inhibition of
virus replication in cultured cells.
HA is the major determinant of virus susceptibility
to NN-DNJ
The distinctive pattern of inhibition of the three viruses by NN-DNJ
was further examined using reassortant viruses to determine
whether the inhibitory pattern correlated with the subtype of
the glycoproteins. First, the effect of NN-DNJ on two high-growth
reassortant vaccine viruses, X-181 (H1N1) and X-171b (H3N2),
reassortant viruses that differ only in their HA and NA genes,
was tested. X-181 contains the HA and NA of the pandemic
H1N1 A/California/7/2009 (HA has 99% sequence identity and
NA has 99.6% sequence identity with Lviv, with no differences in
potential glycosylation sites), and X-171b has the HA and NA of
Zanamivir
(a)  Udorn (H3N2)
– CPNA
+ CPNA
(0.5 mU/mL)
NN-DNJ
0.5 µM 62.5 µM0 DMSO
Zanamivir
(c)  Lviv (H1N1)
– CPNA
+ CPNA
(0.01 mU/mL)
NN-DNJ
0.5 µM 62.5 µM0 DMSO
Zanamivir
(b)  Brisbane/10 (H3N2)
– CPNA
+ CPNA
(0.05 mU/mL)
NN-DNJ
0.5 µM 2.5 µM 62.5 µM0 DMSO
Figure 5. Addition of exogenous CPNA in plaque reduction assays does not restore the plaque size in cells treatedwith NN-DNJ. MDCK cells were infected
with (a) Udorn, (b) Brisbane/10 and (c) Lviv and plaque reduction assays were performed. Concentrations of reagents in the plaque assay overlay are
indicated in the figure. Cells were fixed and stained with toluidine blue at 30 h pi for Udorn, 48 h pi for Brisbane/10 and 40 h pi for Lviv.
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Brisbane/10 (H3N2). Both viruses contain the same six internal
genomic segments derived from PR8.
Single-cycle high-moi assays were performed with X-181,
X-171b, Brisbane/10 and Lviv. Figure 6(a) shows the release of
infectious virus from MDCK cells infected with the four viruses
and treated with increasing concentrations of NN-DNJ. X-171b,
with its HA and NA genes derived from Brisbane/10, was the
most susceptible to inhibition by NN-DNJ and X-181 (H1N1) was
the least susceptible to NN-DNJ (Figure 6a), with each virus show-
ing a different profile. Their IC50 and IC90 values are shown in
Figure 6(a) (ii). From these results, the effects of NN-DNJ on
virus production are determined by the source of the HA and NA
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Figure 6. Susceptibility of reassortant viruses to NN-DNJ compared with wild-type viruses. Infectious virus titres from single-cycle high-moi assays
performed on MDCK cells infected with (a) high-growth vaccine reassortants X-181 and X-171b and wild-type viruses Brisbane/10 and Lviv or (b)
H3N1 reassortant and wild-type viruses Brisbane/10 and Lviv and then treated with NN-DNJ. (c) Plaque reduction assays were performed on MDCK
cells infected with the H3N1 reassortant and wild-type viruses Brisbane/10 and Lviv and then treated with NN-DNJ. Plaques were fixed and
immunostained for NP. In the graphs on the left, means and standard deviations of infectious virus titre of three (a) and two (b and c) independent
experiments are plotted against increasing drug concentration. On the right are summary tables of mean IC50 and IC90 values from independent
experiments described in (a), (b) and (c), respectively;+represents the standard deviations (a) or ranges (b and c) from the mean.
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genes. Although viruses containing the same subtype of HA and
NA but different internal segments (the reassortant versus its
respective wild-type) differed in susceptibility, the reassortant
X-171b and X181 viruses, which contain identical internal genes
but have HA and NA genes from different subtypes, showed dra-
matic differences in susceptibility when compared, reflecting the
susceptibilities seen in the wild-type viruses.
A reassortant H3N1 virus generated between Brisbane/10
(H3N2) and Lviv (H1N1) that contained seven segments from
Brisbane/10 and Segment 6 (encoding NA) from Lviv was used
to determine which segment predominantly determines the
NN-DNJ susceptibility profile of the virus. The effect of NN-DNJ
on this reassortant H3N1 virus was compared with the suscepti-
bility of the parent viruses Brisbane/10 and Lviv to NN-DNJ.
Single-cycle replication assays were performed with all three
viruses (Figure 6b). The reassortant H3N1 was the most suscep-
tible to NN-DNJ of all three viruses tested in this experiment.
IC50 values were obtained for all three viruses (Figure 6b ii). The
mean IC50 values for the three viruses were within 4-fold of
each other; however, the IC90 values for both the reassortant
H3N1 and Brisbane/10 were comparable and an IC90 value was
again not obtained for Lviv. The effects of NN-DNJ on the multi-
cycle replication of the reassortant H3N1 virus were determined
by plaque reduction assay (Figure 6c). A similar trend for reduction
in plaque number was observed for Brisbane/10 and the reassor-
tant H3N1 (Figure 6c). A small reduction in plaque number was
observed for Lviv at the higher concentrations of NN-DNJ (as
shown in Figure 1b iii). This pattern is reflected in the IC50 and
IC90 values summarized in the table in Figure 6(c) (ii). These results
highlight the similarity in susceptibility to NN-DNJ of Brisbane/10
and the reassortant H3N1. While all three viruses had similar IC50
values for plaque size, IC90 values for plaque size obtained for the
reassortant H3N1 and Brisbane/10 coincide (Figure 6c ii).
Therefore, the reassortant H3N1 virus was extremely suscep-
tible to NN-DNJ, as is Brisbane/10, over multiple cycles of replica-
tion. These results indicate that the HA gene most likely
determines NN-DNJ susceptibility, as the NA of Lviv was not suffi-
cient to confer resistance to the H3N1 reassortant.
Discussion
We show that two iminosugars that are known a-glucosidase inhi-
bitors, NB-DNJ and NN-DNJ, exhibit antiviral effects on three
human influenza A viruses: two A(H3N2) viruses Udorn and
Brisbane/10, and the A(H1N1)pdm09 Lviv. An iminosugar
NN-DGJ, which is not an inhibitor of a-glucosidases, showed
muchweaker inhibition.When the effects of the twoa-glucosidase
inhibitors were assessed over a single cycle of virus replication,
NN-DNJ was more effective, with an IC50 over 10-fold lower than
that observed for NB-DNJ. To examine the more potent inhibitor,
NN-DNJ, inmore detail, the inhibition of virus replicationwas exam-
ined over multiple cycles of replication by plaque formation, asses-
sing both plaque number and the size of the virus plaques.
Brisbane/10 was strongly inhibited by NN-DNJ in terms of plaque
number, although Udorn and Lviv showed only a small reduction
in absolute plaque number with NN-DNJ treatment but a signifi-
cant reduction in plaque size. Several previous studies have
reported that a-glucosidase inhibition did not affect the release
of infectious influenza virus,31,33,34,50 but in these studies the
inhibitors were different and the virus strains used were laboratory
strains from the 1930s. Some strain-specific effects of
a-glucosidase inhibition have been observed in a reassortant
H1N8 virus35 and in an H7N1 subtype virus with an inhibitor of
a-glucosidase II, BC.33 Our studies used more recently circulating
viruses and more recently developed a-glucosidase inhibitors.
NN-DNJ, having a longer alkyl chain than NB-DNJ, showed
increased cytotoxicity as well as increased antiviral effects at non-
cytotoxic concentrations. This increased toxicity with increasing
chain length is a general trend shown by iminosugar derivatives;
such effects have been reported by others against different
viruses grown in various cell lines,17,18,51 and correlate with
increased cellular uptake and retention.18,52,53 The stronger anti-
viral effect of DNJ derivatives with long alkyl chains are possibly
due to side-chain effects.22,51,54
Consistent with its action as an inhibitor of a-glucosidases in
the ER, NN-DNJ treatment caused an increase in the amount of
tri-glucosylated structures on influenza glycoproteins, as
assessed by the quantitative MS analysis of glycan composition.
The detection of these structures on secreted virus suggests
that some HAs and NAs were not misfolded sufficiently to lead
to retention in the ER (where this results in accumulation or
ER-associated degradation) and may reflect regional or partial
misfolding of these glycoproteins. Such effects have been seen
previously with, for instance, tyrosinase, which still traffics to mel-
anosomes following a-glucosidase inhibition-induced misfold-
ing55 or with NB-DNJ-induced localized glycoprotein misfolding
confined to the V1/V2 loops of HIV gp120.13 While Lviv HA
grown in the presence of NN-DNJ had the highest proportion of
hyperglucosylated structures, many other factors are likely to
influence susceptibility to iminosugars and this is not evidence
that the Lviv strain is more susceptible to a-glucosidase inhibition.
In fact, our in vitro data suggest that Lviv is the least susceptible to
iminosugars of the three strains tested. The Brisbane/10 HA con-
taineda higher proportion of high-mannose glycans, in comparison
to Udorn and Lviv HA, whichmay reflect the reduced accessibility of
mannose-trimming enzymes. No bi-glucosylated structures were
detected, consistent with the strong inhibition of a-glucosidase I
by NN-DNJ. The distributions of glycoforms were similar to those
quantified on MDCK-grown A/Memphis/1/71 (H3N2),56 such as
the relatively high proportion of high-mannose glycans and the
presence of a-galactose and bisected structures with a core
fucose.
The effects of an NN-DNJ-mediated alteration of glycan pro-
cessing of HA and NA on the influenza A life cycle were examined.
Protein synthesis in drug-treated cells was not markedly affected,
as assessed by the metabolic labelling of virus polypeptides (data
not shown). This observation is in line with those in other studies,
which have shown that treatment with DNJ derivatives does not
affect the protein synthesis of BVDV19,51 or HCV17 and the treat-
ment of MDCK cells with the iminosugars CST, NM-DNJ, homono-
jirimycin and N-methyl-homonojirimycin does not affect the
synthesis of influenza A proteins.31,34,57 Nevertheless, a reduction
in HA expression of Udorn and Brisbane/10 on the surface of
infected cells was observed by immunofluorescence microscopy
on treatment with NN-DNJ but this was not seen in cells infected
with Lviv. The surface expression of the NA of Lviv from
NN-DNJ-treated cells was also not reduced when compared
with control cells (immunostaining of NA from Udorn- and
Brisbane/10-infected cells could not be performed due to a lack
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of suitable antibodies). Therefore, the NN-DNJ-mediated reduc-
tion in HA expression on the cell surface differed between virus
strains. Previous studies have shown that a-glucosidase inhibition
by DNJ or CST did not reduce the cell surface expression of
HA28,35,50 but in those studies prototype viruses first isolated in
the 1930s and propagated extensively since then were examined
and different inhibitors were used.
Both HA and NA bind to calnexin and calreticulin for proper fold-
ing24–29 and misfolded proteins may not be trafficked correctly in
NN-DNJ-treated cells. Our observed reduction in the sialidase activ-
ity of NA synthesized in NN-DNJ-treated cells could be due to a
reduction in mature NA synthesized in cells for the H3N2 viruses
or due to a reduction in the enzymatic activity of a misfolded pro-
tein, but we are currently unable to differentiate between these
possibilities. Nevertheless, a reduced activity of sialidase could
not be complemented by the addition of an exogenous bacterial
NA, unlike the zanamivir-induced inhibition of the release of
virus.36,58 These results suggest that the NN-DNJ inhibited virus
replication at the assembly and/or budding stage, rather than at
the release of virus particles from infected cells.
The two a-glucosidase inhibitors NB-DNJ and NN-DNJ showed
strain-specific antiviral effects whereas the non a-glucosidase
inhibitor NN-DGJ did not. Reassortant viruses that have a PR8
background but carry the HA and NA genes of circulating viruses
show that the strain-specific pattern of inhibition correlated with
the origin of the virus glycoproteins. We observed that the reduc-
tion in sialidase activity of NA synthesized in NN-DNJ-treated cells
did not follow the strain-specific pattern of the NN-DNJ-mediated
inhibition of release of virus, and that the reassortant H3N1 virus
showed similar susceptibility to Brisbane/10 (H3N2) in IC90 values
on NN-DNJ treatment, indicating that drug susceptibility is most
likely determined by the HA, and that the NA of Lviv was not
able to confer relative resistance on this reassortant; this indicates
that the NA is not the main determinant of NN-DNJ inhibition.
However, since the reciprocal reassortant H1N2 virus has not
been made and tested for drug susceptibility, it cannot be
excluded that such a virus may show an effect similar to the
H3N1 virus on drug treatment.
We hypothesize that the differential susceptibility of viral
strains to NN-DNJ treatment may reflect a differential sensitivity
to misfolding or to the consequences of misfolding in any region
where it might occur. For example, any effects of regional misfold-
ing around the receptor-binding site could alter the specific ratio
of HA and NA enzymatic activity to affect the infectivity of strains
differentially. Another potential mechanism to explain differential
strain susceptibility is a variation in assembly of the HA trimers
between strains, with some accommodating misfolding to a
greater or lesser extent. Trimerization is a sequence-specific
event55 so differences in the efficiency of oligomerization of the
HA subunits for individual strains may enhance the a-glucosidase
sensitivity such that we can detect differences in the overall anti-
viral effect. It is notable that we have observed some differences
between the viruses in the relative incorporation efficiency of the
HA into virus particles on treatment with NN-DNJ, which might be
due to misfolding and to a failure to reach the surface of the cell
for assembly and budding. This agrees with the observations pre-
sented and discussed above on the cell surface expression seen
on immunofluorescence microscopy.
It is noteworthy that the glycoproteins of different strains of
influenza virus can differ in the number of N-linked glycosylation
sites andmay also differ in their requirement for glucose-trimming
for maturation. Of the strains used in this study, the recent
A(H3N2) virus Brisbane/10, which was the most susceptible to
NN-DNJ inhibition, has acquired fivemore potential N-linked glyco-
sylation sites in the HA compared with the older Udorn, as previ-
ously noted.59 These extra five glycosylation sites lie in the head
region (reviewed in Skehel and Wiley3). Notably, the pandemic
A(H1N1) virus does not have any glycosylation sites in the head
region. The NA glycoproteins of the three viruses have a similar
number of glycosylation motifs: Brisbane/10 and Lviv having
eight and Udorn seven potential N-linked glycosylation sites.
We have yet to explain the inhibition in cell biological terms. For
example, evidence implies that influenza viruses bud from lipid
rafts (reviewed in Rossman and Lamb60). Budding defects may
occur due to a reduction in the targeting of viral glycoproteins
to lipid rafts due to an alteration in the lipids. DNJ derivatives
with a minimum alkyl chain length of at least three carbons can
inhibit CerGlcT, inhibiting GSL synthesis11 (as do DGJ derivatives),
thus potentially affecting raft formation. Another level at which
these iminosugars may be affecting influenza replication may
be on virus entry due to a reduction in the number of virus recep-
tors, sialic acids, expressed on glycoconjugates on the cell surface
by an inhibition of GSL synthesis (DNJ and DGJ derivatives) and
a-glucosidase inhibition (DNJ derivatives). Future work will include
examining relative viral protein turnover levels in cells and charac-
terizing the effects of iminosugars on glycoprotein folding, trimer-
ization and function, in addition to the effects on virus entry and
assembly.
If the safety and efficacy of iminosugars as antivirals for influ-
enza in humans were to be established, these drugs might be
administered in combination with drugs targeting viral proteins
to patients suffering from severe illness, and alone to those
infected with multiple drug-resistant strains or those who are
unable to take other available anti-influenza drugs due to under-
lying complications.
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